Praxis Precision Medicines, Inc. Expected to Earn Q2 2023 Earnings of ($1.36) Per Share (NASDAQ:PRAX)

Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Rating) – Analysts at William Blair issued their Q2 2023 earnings per share (EPS) estimates for shares of Praxis Precision Medicines in a research note issued on Thursday, April 28th. William Blair analyst M. Minter expects that the company will post earnings per share of ($1.36) for the quarter.

Shares of NASDAQ PRAX opened at $8.10 on Monday. The business has a fifty day moving average price of $10.89 and a two-hundred day moving average price of $15.39. The stock has a market capitalization of $368.60 million, a PE ratio of -2.08 and a beta of 2.29. Praxis Precision Medicines has a fifty-two week low of $7.48 and a fifty-two week high of $31.88.

Praxis Precision Medicines (NASDAQ:PRAX – Get Rating) last posted its earnings results on Monday, February 28th. The company reported ($1.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.08) by ($0.22).

Several hedge funds and other institutional investors have recently modified their holdings of PRAX. Deutsche Bank AG raised its stake in Praxis Precision Medicines by 24.5% in the third quarter. Deutsche Bank AG now owns 21,123 shares of the company’s stock valued at $391,000 after purchasing an additional 4,159 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in Praxis Precision Medicines by 44.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,136,995 shares of the company’s stock valued at $21,023,000 after buying an additional 350,000 shares during the period. California State Teachers Retirement System increased its holdings in Praxis Precision Medicines by 5.1% in the 3rd quarter. California State Teachers Retirement System now owns 35,358 shares of the company’s stock valued at $654,000 after buying an additional 1,726 shares during the period. The Manufacturers Life Insurance Company boosted its position in Praxis Precision Medicines by 22.2% in the third quarter. The Manufacturers Life Insurance Company now owns 17,775 shares of the company’s stock valued at $329,000 after buying an additional 3,232 shares in the last quarter. Finally, Veritable L.P. bought a new stake in shares of Praxis Precision Medicines during the third quarter worth $220,000. Institutional investors own 96.52% of the company’s stock.

About Praxis Precision Medicines (Get Rating)

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor.

Recommended Stories